Radiant Research, Inc., a leading provider of clinical and consumer product testing, has expanded its consumer division.
Radiant Research, Inc., a leading provider of clinical and consumer product testing, has expanded its consumer division. This expansion includes additional geographic locations and increased product testing capabilities. The changes give Radiant’s consumer testing sites the ability to conduct studies in more diverse dermatological disease states, as well as in a varied demographical healthy normal population, with new bioinstrumentation resources.
“Radiant has become an industry leader in complex consumer trials since launching this specialized division in 2011,” said Tara Kelley, vice president of operations for Radiant Research. “Now, we’re giving our clients more options for their consumer testing needs by adding new locations and specialty populations. We’ve also made the process more efficient by integrating our consumer product and clinical trial database – giving us access to one million potential study participants.”
As part of its commitment to safe, effective and efficient consumer product testing, Radiant Research staffs clinical coordinators, recruitment specialists, technicians and medical research specialists at each site. Additionally, the sites are supported by a central team of experienced professionals who provide resources that are unmatched in the industry.
In addition to the wide range of claim support studies, Radiant Research has expanded its Dermal Safety testing to include the following: Cumulative Irritation, Phototoxicity, Contact Sensitization, Primary Irritation, Photoallergy and Transdermal Delivery Systems at multiple locations.
Radiant Research encourages those with consumer product testing needs to visithttp://www.radiantresearch.com and contact Charley Folk at 480-699-3406 or [email protected].
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.